135 related articles for article (PubMed ID: 25327965)
1. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study.
Pinato DJ; Karamanakos G; Arizumi T; Adjogatse D; Kim YW; Stebbing J; Kudo M; Jang JW; Sharma R
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1270-81. PubMed ID: 25327965
[TBL] [Abstract][Full Text] [Related]
2. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
Pinato DJ; Sharma R
Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
[TBL] [Abstract][Full Text] [Related]
3. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
[TBL] [Abstract][Full Text] [Related]
4. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation.
Mishra G; Dev A; Paul E; Cheung W; Koukounaras J; Jhamb A; Marginson B; Lim BG; Simkin P; Borsaru A; Burnes J; Goodwin M; Ramachandra V; Spanger M; Lubel J; Gow P; Sood S; Thompson A; Ryan M; Nicoll A; Bell S; Majeed A; Kemp W; Roberts SK;
BMC Cancer; 2020 May; 20(1):483. PubMed ID: 32471447
[TBL] [Abstract][Full Text] [Related]
6. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
7. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
9. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
10. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
11. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
12. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
13. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
14. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.
Zheng Q; Xu X; Weng J; Li M; Li B; Cao Y
Free Radic Biol Med; 2024 Aug; 221():225-234. PubMed ID: 38815771
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.
Han G; Berhane S; Toyoda H; Bettinger D; Elshaarawy O; Chan AWH; Kirstein M; Mosconi C; Hucke F; Palmer D; Pinato DJ; Sharma R; Ottaviani D; Jang JW; Labeur TA; van Delden OM; Pirisi M; Stern N; Sangro B; Meyer T; Fateen W; García-Fiñana M; Gomaa A; Waked I; Rewisha E; Aithal GP; Travis S; Kudo M; Cucchetti A; Peck-Radosavljevic M; Takkenberg RB; Chan SL; Vogel A; Johnson PJ
Hepatology; 2020 Jul; 72(1):198-212. PubMed ID: 31698504
[TBL] [Abstract][Full Text] [Related]
16. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.
Shi ZX; Li CF; Zhao LF; Sun ZQ; Cui LM; Xin YJ; Wang DQ; Kang TR; Jiang HJ
Hepatobiliary Pancreat Dis Int; 2024 Aug; 23(4):361-369. PubMed ID: 37429785
[TBL] [Abstract][Full Text] [Related]
17. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
[TBL] [Abstract][Full Text] [Related]
18. Tumour stiffness associated with tumour response to conventional transarterial chemoembolisation for hepatocellular carcinoma: preliminary findings.
Chen R; Kong W; Gan Y; Ge N; Chen Y; Ding H; Luo J; Wang W; Ren Z
Clin Radiol; 2019 Oct; 74(10):814.e1-814.e7. PubMed ID: 31421865
[TBL] [Abstract][Full Text] [Related]
19. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
